It’s good news in the fight against colorectal cancer: A new test can detect the disease with a simple blood draw. But don’t cancel your colonoscopy just yet — that old standby is still more reliable ...

A second blood test shows promise for the detection of colon cancer, according to a new study. The first, called Shield, was approved by the Food and Drug Administration in July for people 45 and ...

Kentucky has one of the highest rates of colorectal cancer in the US, but early detection leads to a 91% five-year survival rate. Colorectal cancer is projected to become the leading cancer killer for ...

Created by Guardant Health, the blood test, known as Shield, was able to detect 83% of colorectal cancers in studies but only 13% of dangerous polyps. Colonoscopies find approximately 95% of these ...

In 2024, the Food and Drug Administration (FDA) approved a blood test that can screen for colorectal cancer in people older than 45 years old at average risk for the disease. Some people may skip ...

The newest version of Cologuard, an at-home colon cancer screening test, results in fewer false positives that can lead to ...

Time for a rear-ality check. Colorectal cancer rates have been rising among adults younger than 50 since the 1990s, a troubling trend that has perplexed scientists. Because of the increase in cases, ...

The U.S. Preventive Services Task Force recommends colorectal cancer screening for all adults starting at age 45. After age 75, the task force recommends talking with your health care team to decide ...

Studies using the three-card, take-home method of FOBT screening repeated over a number of years have demonstrated mortality reductions of up to 33%. Conversely, there are no large studies documenting ...

Colonoscopies are considered the gold standard for detecting colorectal cancer. But some dread the idea of the invasive procedure and the prep required the day before you have it. The FDA last year ...

A blood test that accurately detects colon cancer in middle-aged and older people and also rules it out when it is not present can help to increase the rate of screening for the disease in the U.S.